神经母细胞瘤 z-bo 2020-10-09 328

　　In the Phase II clinical trial of neuroblastoma at St. Jude Children’s Research Hospital, researchers used experimental monoclonal antibodies to develop 80% of newly diagnosed high-risk young neuroblastoma patients.

　　Of the 34 children and Qin juvenile neuroblastoma patients, 13 had no signs of disease at all, and 4 patients had been treated with the experimental unit for at least 18 months. finished. While undergoing clonal antibody therapy, he received multi-drug chemotherapy, surgery, radiotherapy, and stem cell transplantation. Two patients with persistent disease received other treatments, and two of them died due to toxic effects. Neuroblastoma is a cancer caused by immature nerve cells in the sympathetic nervous system. In the United States, there are approximately 700 new patients each year, most of whom are children or adolescents over five years old. In this study, patients began to use the drug cyclophosphamide in combination with topotecan chemotherapy, and treated with the experimental monoclonal antibody hu14.18K322A.

　　After two rounds of treatment, researchers found that 80% of the patients' primary tumors shrank by 47% to 96%, and the rest stopped growing. In a similar patient previously employed, the researchers found that the hu14.18K322A treatment was not combined with the same chemotherapeutic drugs. Only 40% of the patients’ tumors are small. Hu14.18K322A is an antibody therapy developed in the laboratory. It can activate the body's immune response to tumor cells by recognizing and binding to most antigens on the surface of neuroblastoma cells.

　　This antigen is also called GD2 and the binding of anti-GD2 monoclonal antibody to pain fibers is located on the surface of melanoma, osteosarcoma and soft tissue sarcoma cells, which can cause more severe pain. In this study, the new monoclonal antibody therapy hu14.18K322A developed by the researchers can effectively reduce the pain associated with other GD2 monoclonal antibody therapies. For hu14.18K322A treatment, the researchers used hu14.18. Mutations in protein spots can eliminate the cascade activation effect of complement, which is thought to cause treatment-related physical pain. At the same time, the composition of this monoclonal antibody therapy in mice is very low, so the body's immune system is unlikely to attack itself. Researcher Feynman said that intravenous pills may be able to effectively control the pain caused by antibody pretreatment. This new monoclonal antibody therapy is currently undergoing phase II clinical trials, and researchers hope that antibody therapy will become a new type of therapy for effective treatment of neuroblastoma in the future.